Postoperative *Staphylococcus aureus* (SA) infections continue to cause substantial morbidity and mortality \[[@OFU071C1]--[@OFU071C3]\]. Invasive infections such as mediastinitis negatively impact both short- and long-term survival after heart operations \[[@OFU071C4]\]. Active surveillance and selective decolonization, universal decontamination, perioperative interventions (including the choice and duration of antibiotic prophylaxis), and targeted immunization have all been used to reduce the incidence of SA infections with inconsistent success \[[@OFU071C5]--[@OFU071C12]\]. Infections after cardiothoracic surgery have come under increased scrutiny from payers and are now considered never-events by Medicare. Implementation of pay-for-performance measures governing postoperative infections has further spurred interventions to reduce this serious complication.

Efficient implementation of preventive measure requires contemporary knowledge of postoperative SA infection rates, modifiable risk factors, and impact on surgical outcomes. An international, double-blind, randomized placebo-controlled Phase IIb/III trial of a novel SA vaccine (V710; Merck) was recently completed in 7664 adults scheduled for full median sternotomy \[[@OFU071C12]\]. As previously reported, V710 was not efficacious in preventing SA bacteremia and/or deep sternal wound infection based on predefined criteria for efficacy. Although overall survival rates were not significantly different for vaccine and placebo recipients, vaccine recipients who later developed postoperative SA infections had a higher mortality rate than placebo recipients with SA infections. Using the data from the 3832 placebo recipients enrolled in the V710-P003 trial, we analyzed the incidence, timing, risk, and consequences of postoperative SA infections in this large contemporary international cohort.

METHODS {#s2}
=======

Design of Parent Study {#s2a}
----------------------

V710-P003 (ClinicalTrials.gov NCT00518687) was a randomized, multicenter, placebo-controlled double-blind, group-sequential clinical trial conducted worldwide from 2007 to 2011 to evaluate the efficacy, immunogenicity, and safety of a single dose of the Merck SA vaccine (V710) in adult patients scheduled for cardiothoracic surgery via full median sternotomy \[[@OFU071C12]\]. Conduit harvesting and operative techniques, type and duration of perioperative antibiotic prophylaxis, and other interventions were not standardized across the 164 sites. The primary endpoints were postoperative bacteremia and/or deep sternal wound infection (including mediastinitis) caused by SA, but all SA infections were to be reported and adjudicated using standardized definitions for SA infections adapted from the Centers for Disease Control and Prevention Guidelines for Nosocomial Infections \[[@OFU071C13]\]. Mediastinitis was categorized as a subset of deep sternal wound infection with documented mediastinal involvement by culture or inspection. Patients exhibiting evidence of a postoperative infection (including fever, leukocytosis, severe sternal pain or instability, wound drainage, or other concerning symptoms or signs) were to be comprehensively evaluated. The assessment was explicitly detailed for suspected infections during the primary 90-day postoperative time frame in the protocol.

Preoperative colonization with SA was determined by culture of a single nasal swab taken at study entry 14--60 days before the scheduled operation and processed according to local custom. Decontamination was not mandated by protocol, and techniques were not standardized across sites. Systematic information in this regard was neither prospectively collected nor retrospectively retrievable in a consistent fashion. Knowledge of colonization status at the time of operation may have influenced perioperative management at some sites.

Exploratory Analyses {#s2b}
--------------------

The main objective of the current post hoc hypothesis-generating analyses was to describe the incidence and implications of postoperative SA infections complicating cardiothoracic surgery in contemporary practice worldwide. We were particularly interested in preoperative SA colonization and other possible risk factors for postoperative infection. Because receipt of V710 may have perturbed or confounded some outcome measures (such as the mortality rate after postoperative SA infection \[[@OFU071C11]\]), we limited the current analysis to placebo recipients.

An inclusive secondary modified intention-to-treat population of placebo recipients from the V710-P003 trial (composed of all 3832 placebo recipients who underwent any cardiothoracic procedure without incurring a serious preoperative SA infection) was selected for analysis. Every SA infection (whether or not adjudicated) up to 360 days postoperatively (despite the protocol-stipulated 90-day postoperative period for the primary efficacy analysis) was included \[[@OFU071C12]\]. Results from a single site that did not adhere to good clinical practices were excluded here because the data were deemed unreliable.

A subject was considered to have methicillin-resistant SA (MRSA) infection if any of the pertinent cultures were positive for MRSA. Nominal *P* values were computed post hoc for selected comparisons by the Pearson χ^2^ or Wilcoxon rank-sum tests without correction for multiplicity. Asymptotic confidence limits for the relative risk were based on the standard normal distribution.

RESULTS {#s3}
=======

From December 17, 2007 to April 8, 2011, a total of 8010 patients from 164 sites in 26 countries were enrolled, 7963 participants received vaccine or placebo, and 7647 subjects (including 3832 placebo recipients) ultimately underwent cardiothoracic surgery between 14 and 60 days postvaccination. All 21 randomized participants (12 to the V710 arm and 9 to the placebo arm) from one site with questionable clinical practices discovered during multiple audits were excluded from the current analyses; there were no infections in the placebo group at this hospital. The large majority (\>99%) of procedures involved a median sternotomy. Overall, 80.8% (3096 of 3832) of placebo recipients underwent coronary artery or cardiac valve operations, including coronary artery bypass grafting in 41.7% (1598 of 3832) (Table [1](#OFU071TB1){ref-type="table"}). Table 1.Baseline Characteristics for the Placebo Group in the MITT Population^a^No SA InfectionAny SA InfectionMSSA InfectionMRSA InfectionN = 3712N = 120N = 97N = 23Gender, *n* (%) Male2487 (67.0)79 (65.8)63 (64.9)16 (69.6) Female1225 (33.0)41 (34.2)34 (35.1)7 (30.4)Self-identified Race, *n* (%) White2834 (76.3)110 (91.7)93 (95.9)17 (73.9) Black71 (1.9)0 (0.0)0 (0.0)0 (0.0) Asian514 (13.8)5 (4.2)3 (3.1)2 (8.7) Multiracial282 (7.6)4 (3.3)1 (1.0)3 (13.0) Other or Unknown11 (0.3)1 (0.8)0 (0.0)1 (4.3)Self-reported Ethnicity, *n* (%) Hispanic or Latino824 (22.2)14 (11.7)9 (9.3)5 (21.7)Region, *n* (%) Asia/Pacific501 (13.5)5 (4.2)3 (3.1)2 (8.7) Europe/Russia1844 (49.7)82 (68.3)75 (77.3)7 (30.4) Latin America657 (17.7)11 (9.2)6 (6.2)5 (21.7) United States710 (19.1)22 (18.3)13 (13.4)9 (39.1)Age Median (range), years66 (19--93)66 (36--85)66 (40--85)70 (36--83) ≥70 years, *n* (%)1393 (37.5)47 (39.2)35 (36.1)12 (52.2)Underlying metabolic conditions, *n* (%) Diabetes mellitus878 (23.7)48 (40.0)^b^35 (36.1)13 (56.5) BMI ≥ 30 kg/m^2^939 (25.3)51 (42.3)^b^45 (46.4)6 (26.1) Diabetes and BMI ≥ 30355 (9.6)31 (25.8)26 (26.8)5 (21.7)Society of Thoracic Surgeons infection-risk score^c^ Median (range)6 (0--26)8.5 (0--26)8 (0--26)9 (0--19)Nasal colonization, *n* (%) Colonized by SA652 (17.6)49 (40.8)^b^42 (43.3)7 (30.4)  with MSSA595 (16.0)46 (39.3)^b^42 (43.3)4 (17.4)  with MRSA57 (1.5)3 (2.5)0 (0.0)3 (13.0)Type of cardiothoracic surgery,^d^ *n* (%) CABG only1181 (31.8)60 (50.0)48 (49.5)12 (52.2) Aortic valve973 (26.2)18 (15.0)14 (14.4)4 (17.4) Mitral valve479 (12.9)5 (4.2)3 (3.1)2 (8.7) Tricuspid valve23 (0.6)0 (0.0)0 (0.0)0 (0.0) CABG and valve339 (9.1)18 (15.0)17 (17.5)1 (4.3) Other717 (19.3)19 (15.8)15 (15.5)4 (17.4)Full median sternotomy Number (%) of patients3688 (99.4)119 (99.2)96 (99.0)23 (100)Timing of infection Median \[IQR\] POD^e^28.5 \[16.5--45\]28 \[19--42\]40 \[13--63\] Number (%) of patients  \<14 days19 (15.8)13 (13.4)6 (26.1)  14--40 days63 (52.5)57 (58.8)6 (26.1)  41--60 days18 (15.0)14 (14.4)4 (17.4)  61--90 days11 (9.2)6 (6.2)5 (21.7)  \>90 days9 (7.5)7 (7.2)2 (8.7)[^2][^3][^4][^5][^6][^7]

A postoperative SA infection of any kind or severity was reported in 120 (3.1%) of the 3832 placebo recipients. Methicillin-resistant SA was recovered from 23 cases (19%). Invasive SA infections including bacteremia and deep sternal-wound infection (with or without mediastinitis) occurred in 39 patients (1%), accounting for 33% of the 120 total observed infections (Table [2](#OFU071TB2){ref-type="table"}). Overall, superficial wound infections were the most common type of SA infections reported in our patients (Table [3](#OFU071TB3){ref-type="table"}). Nine infections (7.5%) were diagnosed \>90 days postoperatively (Table [4](#OFU071TB4){ref-type="table"}). Table 2.Outcomes for Placebo Recipients With and Without Postoperative SA Infections in the MITT Population During the Entire Study^a,b^No SA InfectionAny SA InfectionMSSA InfectionMRSA InfectionN = 3712N = 120N = 97N = 23Type of SA Infection, *n* Any1209723 Invasive392613 Bacteremia25196 Deep sternal wound1174All-cause Mortality, *n* (%) Died153 (4.1)11 (9.2)7 (7.2)4 (17.4) Had SA bacteremia5 (4.2)4 (4.1)1 (4.3)[^8][^9][^10] Table 3.Types of Postoperative SA Infections in Placebo Recipients Diagnosed Anytime During the Study^a^CategoryPlacebo Group*N*%Subjects randomized to placebo arm4005Subjects given placebo3982Placebo recipients in the MITT population3832Patients with SA infections of any type or severity1203.1Patients with any invasive SA infections391.0Patients with SA bacteremia and/or DSWI (primary endpoints)330.9Patients with any SA SSI972.5Specific infections (in alphabetical order)n% Aortic root abscess1\<0.1 Bacteremia250.7 Deep incisional SSI at leg or arm donor/harvest site70.2 DSWI with mediastinitis100.3 DSWI without mediastinitis1\<0.1 Endocarditis40.1 Noninvasive skin/soft tissue infection50.1 Osteomyelitis1\<0.1 Pancreatic abscess1\<0.1 Pneumonia90.2 Septic arthritis (knee prosthesis)1\<0.1 Superficial incisional SSI at chest incision site260.7 Superficial incisional SSI at leg or arm donor/harvest site401.0 Superficial incisional SSI at catheter or tube insertion site80.2 Tracheobronchitis2\<0.1 Urinary tract infection1\<0.1[^11][^12] Table 4.Types of Postoperative *Staphylococcus aureus* Infections in Placebo Recipients Diagnosed After Postoperative Day 90Postoperative Day*Staphylococcus aureus* Infection Code91DEEP INCISIONAL SURGICAL SITE INFECTION - right leg venectomy site96NONINVASIVE INFECTION100SUPERFICIAL INCISIONAL SURGICAL SITE INFECTION -- harvest site104BACTEREMIA153SUPERFICIAL INCISIONAL SURGICAL SITE INFECTION -- chest site162SUPERFICIAL INCISIONAL SURGICAL SITE INFECTION - harvest site178BACTEREMIA246NONINVASIVE INFECTION319INVASIVE INFECTION PNEUMONIA

*Staphylococcus aureus* infections occurred relatively more often after coronary artery bypass grafting with or without valve surgery than after other cardiothoracic procedures (relative risk = 1.59, 95% confidence interval \[CI\], 1.38, 1.82). Compared with patients without SA infection, patients with SA infections more often had a body mass index (BMI) ≥ 30 kg/m^2^ (42% \[51 of 120\] vs 25% \[939 of 3712\]; relative risk = 1.68 \[95% CI, 1.35, 2.08\], *P* \< .001) and diabetes (40% \[48 of 120\] vs 24% \[878 of 3712\]; relative risk = 1.69 \[95% CI, 1.35, 2.12\], *P* \< .001). Both diabetes and a BMI ≥ 30 kg/m^2^ were present in 25.8% of infected patients compared with 9.6% of uninfected patients. Of the 97 methicillin-susceptible SA (MSSA) infections, 35 (36.1%) occurred in diabetic patients; in contrast, 13 (56.5%) of the 23 MRSA infections occurred in diabetic patients. Numerical differences in SA infection rates and patterns were observed across continents. Infection rates were different even at a country level, but small numbers of patients and variations in operating procedures at the site level precluded detailed analysis. Methicillin-resistant SA infections were more often invasive and diagnosed later than MSSA infections (median postoperative day 40 vs 28, *P* \> .05). All-cause mortality rate was 4.1% (153 of 3712) in patients without SA infection, compared with 7.2% (7 of 97) in MSSA infections and 17.4% (4 of 23) in MRSA infections (*P* \< .01).

*Staphylococcus aureus* nasal carriage was detected preoperatively by culture in 18.3% (701 of 3832) of placebo recipients, including 1.6% (60 of 3832) colonized with MRSA. *Staphylococcus aureus* infections developed postoperatively in 49 of 701 (7.0%) of colonized patients at baseline vs 71 of 3131 (2.3%) of patients without detected colonization (relative risk = 3.1 \[95% CI, 2.2, 4.4\], *P* \< .001) (Table [5](#OFU071TB5){ref-type="table"}). Baseline nasal colonization rates were 41% (49 of 120) in patients who developed postoperative SA infections compared with 18% (652 of 3712) in patients without postoperative SA infection (*P* \< .001). The likelihood of a postoperative SA infection was numerically higher with preoperative MSSA colonization (7.2%) than with preoperative MRSA colonization (5.0%), but this difference was not statistically significant (*P* \> .50). All 3 patients with preoperative MRSA colonization who subsequently developed postoperative SA infections were infected by MRSA, but these cases represent the only 3 (13%) of the 23 postoperative MRSA infections associated with preoperative MRSA colonization. On the other hand, MRSA infections developed in 4 (9%) of 46 patients colonized with MSSA. Table 5.Predictive Value of Preoperative SA Nasal Carriage for Postoperative SA InfectionResults of Preoperative SA Nasal CultureNumber With Postoperative SA InfectionNumber Without Postoperative SA InfectionProbability of Postoperative SA InfectionNegative7130602.3%Positive496527.0% MSSA465957.2% MRSA3575.0%Totals12037213.1%[^13]

DISCUSSION {#s4}
==========

*Staphylococcus aureus* remains an important cause of postoperative complications despite advances in surgical practices worldwide. The most serious invasive SA infections including bacteremia and deep sternal wound infections currently complicate cardiothoracic procedures involving median sternotomy in ∼1% of adult patients worldwide \[[@OFU071C1]--[@OFU071C4]\]. In our analysis of placebo recipients from a randomized, event-driven, double-blinded clinical trial, SA infections occurred relatively more often after coronary artery bypass grafting than after other cardiothoracic procedures. The majority of SA infections were superficial wound infections involving the sternal incision or vein harvest site. Methicillin-resistant SA caused 19% of the 120 postoperative SA infections. The all-cause mortality rate was 4.1% in patients without SA infection, compared with 7.2% for MSSA infections and 17.4% for MRSA infections. Although potentially confounded by covariates, attributable mortality rates for MSSA infections can be crudely estimated at 3% and 13% for MRSA infections, attesting to the continued high case-fatality rate of this postoperative complication.

The postoperative SA infection risk was threefold higher in patients with preoperative nasal colonization as determined by cultures of nasal swabs obtained 14--60 days before surgery. A total of 49 postoperative SA infections occurred in 701 patients with positive nasal cultures out of the 3832 patients who were cultured, yielding a positive predictive value of 7.0% (the risk of developing a postoperative SA infection in colonized patients). The negative predictive value was a 97.7%, translating into a 2.3% chance of developing a postoperative SA infection in uncolonized patients. The substantial majority of postoperative SA infections (71 of 120, 59%) occurred in patients where our nasal culturing technique did not detect SA at baseline. The number needed to culture preoperatively to identify 1 patient at high risk for a potentially preventable postoperative SA infection was 78 (3832 cultures/49 infections possibly prevented).

A recent interventional study using polymerase chain reaction (PCR) of nasal swabs for screening found an almost identical infection rate (7.8%) in untreated patients as observed in our population \[[@OFU071C14]\]. The effect of preoperative application with mupirocin nasal ointment and chlorhexidine bathing in colonized patients reduced the SA infection rate from 7.7% to 3.4%, being most pronounced with respect to deep surgical-site infections. The crude mortality rate was not significantly reduced by the decolonization procedures, but the study was not powered to assess overall survival. Unlike that trial, we unfortunately could not determine whether the 7% infection rate in our study represents the incidence for patients in whom decolonization was or was not attempted. On the other hand, because it is unlikely that decolonization procedures would increase the risk of infection, we can plausibly conclude that the infection rate in nasally colonized patients is no less than 7%.

These exploratory analyses have several obvious and important limitations. Our study was a post hoc hypothesis-generating analysis of a relatively small number of events undertaken after the study data were unblinded without a matched control group. Perioperative and surgical approaches were performed according to the local standard of care and therefore were not uniform across sites. The international nature of the clinical trial undoubtedly adds a substantial degree of inhomogeneity in surgical practices. Infections other than those caused by SA were not systematically recorded, and thus their impact on morbidity and mortality are unknown. Only surveillance cultures of the nares were performed to assess colonization; PCR techniques were not routinely utilized and extranasal sites were not sampled. Screening a single anatomical site exclusively by culture techniques may have failed to detect a sizeable number of SA carriers \[[@OFU071C15]\]. Missing SA carriage in the throat, axilla, or groin could result in an underestimation of the effect of colonization on postoperative outcomes along with an overestimation of the number of patients needed to be screened to potentially reduce the risk of infectious complications. The infecting and colonizing SA strains were not typed in the majority of cases so identity could not be established. Management of nasal carriage was not prescribed by protocol, and the approach to positive nasal cultures was neither standardized nor systemically recorded. If decolonization was attempted and accomplished sporadically in our study population, eradication of SA in some carriers could have surreptitiously reduced the postsurgical infection rates in our colonized patients; consequently, our observed infection rate of 7% may actually represent an artificially low incidence for untreated colonized patients. Knowledge of the antimicrobial susceptibilities of the colonizing strain could have influenced the choice and duration of antibiotic prophylaxis at the time of the procedure.

Although SA infections developed after median sternotomy in only 7% of cardiothoracic-surgical patients colonized in the nares at baseline, the risk of postoperative SA infection was \>3 times higher than for patients without culture-documented nasal carriage \[[@OFU071C14], [@OFU071C16]\]. Pre- and peri-operative strategies aimed at reducing postoperative SA infections in high-risk surgical patients, such as selective vs universal decolonization, prophylactic antibiotic selection based on susceptibility results for the colonizing strain, or enhancement of immune surveillance, deserve further cost-effectiveness analyses \[[@OFU071C6]--[@OFU071C11], [@OFU071C14], [@OFU071C16]--[@OFU071C22]\].
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[^1]: Present affiliation: The Bill and Melinda Gates Foundation, New York, New York.

[^2]: Abbreviations: BMI, body mass index; CABG, coronary artery bypass grafting; IQR, interquartile range; MITT, modified intention to treat; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-sensitive *S aureus*; POD, postoperative day; SA, *Staphylococcus aureus*.

[^3]: ^a^ The secondary modified intention-to-treat population of placebo recipients from the V710-P003 trial (used for the current analysis) was composed of all 3832 placebo recipients who underwent any cardiothoracic procedure without incurring a serious preoperative *S aureus* infection. The 21 patients randomized at the site with questionable clinical practices (12 to the V710 arm and 9 to the placebo arm) have been excluded from this table and all analyses.

[^4]: ^b^ Nominal *P* \< .001 for SA-infected vs noninfected patients; *P* values for all other pairwise comparisons between SA-infected and noninfected subgroups were \>.05.

[^5]: ^c^ Adapted from Fowler et al \[[@OFU071C4]\].

[^6]: ^d^ The type of cardiothoracic procedure was collected using the case-report form which contained the prespecified choices listed in the above table. The "Other" category was a free-text field that could have included procedures either specified or not listed on the form in various combinations as entered by the site investigator.

[^7]: ^e^ The median follow-up time for placebo recipients without infection was 359 days (IQR = 254--366 days).

[^8]: Abbreviations: MITT, modified intention to treat; MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-sensitive *S aureus*; SA, *Staphylococcus aureus*.

[^9]: ^a^ All adjudicated and nonadjudicated endpoints were tabulated up to 360 days postoperatively. Patients could be included in \>1 subcategory of infection. A patient was considered to have MRSA infection if at least 1 culture grew MRSA.

[^10]: ^b^ The secondary modified intention-to-treat population used for the present analysis included all 3832 placebo recipients who underwent any type of cardiothoracic operation after vaccination. The 21 patients randomized at the 1 site with questionable clinical practices (12 to the V710 arm and 9 to the placebo arm) have been excluded from these analyses. There were no SA infections of any type in placebo recipients from the excluded site, although 1 V710 recipient reached the primary endpoint of SA bacteremia.

[^11]: Abbreviations: DSWI, deep sternal wound infection; MITT, modified intention to treat; N, number of patients with the specified infection (% with specified infection); n, number of infections; SA, *Staphylococcus aureus*; SSI surgical site infection.

[^12]: ^a^ Patients may have had multiple infections and be included in multiple categories.

[^13]: Abbreviations: MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-sensitive *S aureus*; SA, *Staphylococcus aureus*.
